2K3 Stock Overview A medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
SI-BONE, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for SI-BONE Historical stock prices Current Share Price US$13.40 52 Week High US$19.90 52 Week Low US$11.00 Beta 1.18 1 Month Change -8.84% 3 Month Change 6.35% 1 Year Change -27.96% 3 Year Change -31.28% 5 Year Change -29.47% Change since IPO -19.95%
Recent News & Updates
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2023) Nov 14
SI-BONE, Inc. Updates Financial Guidance for the Year 2024 Nov 14
SI-BONE, Inc. Updates Financial Guidance for the Year 2024 Nov 13
SI-BONE, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 23
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation Oct 10
CEO & Director recently sold €126k worth of stock Aug 22 See more updates
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2023) Nov 14
SI-BONE, Inc. Updates Financial Guidance for the Year 2024 Nov 14
SI-BONE, Inc. Updates Financial Guidance for the Year 2024 Nov 13
SI-BONE, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 23
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation Oct 10
CEO & Director recently sold €126k worth of stock Aug 22
Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.30 loss in 2Q 2023) Aug 06
SI-BONE, Inc. Revises Financial Guidance for 2024 Aug 06
New minor risk - Share price stability Jul 31
SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 16
New minor risk - Share price stability Jun 12
Si-Bone, Inc. Increases Revenue Guidance for 2024 May 08
First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.32 loss in 1Q 2023) May 07
Insufficient new directors May 01
SI-BONE, Inc., Annual General Meeting, Jun 25, 2024 May 01
SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 16
New minor risk - Profitability Mar 01
SI-BONE, Inc. Provides Earnings Guidance for the Year 2024 Feb 29
Full year 2023 earnings released: US$1.13 loss per share (vs US$1.79 loss in FY 2022) Feb 27
Forecast to breakeven in 2026 Feb 27
CEO & Director recently sold €751k worth of stock Feb 23
SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 06
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application Jan 30
Forecast to breakeven in 2026 Jan 20
SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 Jan 09
Executive Chairman recently sold €130k worth of stock Nov 24
SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023 Nov 09
Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.41 loss in 3Q 2022) Nov 09
New major risk - Revenue and earnings growth Nov 08
SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 17
SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods Sep 06
CEO & Director recently sold €173k worth of stock Aug 21
Independent Director recently sold €561k worth of stock Aug 13
SI-BONE, Inc. Revises Revenue Guidance for the Year 2023 Aug 10
Second quarter 2023 earnings released: US$0.30 loss per share (vs US$0.54 loss in 2Q 2022) Aug 08
SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 18
CEO & Director recently sold €206k worth of stock May 22 SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million. May 06
First quarter 2023 earnings released: US$0.32 loss per share (vs US$0.52 loss in 1Q 2022) May 03
SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 07
SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022 Jan 10
SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System Dec 28
Executive Chairman recently sold €101k worth of stock Nov 19
Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.48 loss in 3Q 2021) Nov 09
SI-BONE, Inc. Updates Revenue Guidance for the Year 2022 Nov 08
SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 18
Executive Chairman recently sold €135k worth of stock Aug 19
SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022 Aug 10
Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.42 loss in 2Q 2021) Aug 09
SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 19
SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System Jun 14
SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite Jun 01
Executive Chairman recently sold €68k worth of stock May 20
First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.37 loss in 1Q 2021) May 11 SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022 May 10
SI-BONE, Inc., Annual General Meeting, Jun 16, 2022 Apr 23
SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment Apr 20
SI-BONE, Inc. to Report Q1, 2022 Results on May 09, 2022 Apr 19
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 02
SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022 Mar 02
Executive Chairman recently sold €80k worth of stock Feb 18
SI-BONE, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 02
Executive Chairman recently sold €122k worth of stock Nov 18
Third quarter 2021 earnings released: US$0.48 loss per share (vs US$0.33 loss in 3Q 2020) Nov 09
Executive Chairman recently sold €120k worth of stock Aug 18
Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.44 loss in 2Q 2020) Aug 04
SI-BONE, Inc. Provides Earnings Guidance for the Year 2021 Aug 04
Executive Chairman recently sold €52k worth of stock Jul 22
Si-Bone, Inc. Announces the Introduction of the Si-Bone Simulator Powered by Medability for Ifuse Surgeon Training and Education Jul 03
Independent Director Mark Foley has left the company Jun 15
Independent Director Karen Licitra has left the company Jun 15
Executive Chairman recently sold €217k worth of stock May 21
First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.47 loss in 1Q 2020) May 05
Si-Bone, Inc. Provides Revenue Guidance for the Year 2021 May 04
Executive Chairman & President recently sold €59k worth of stock Apr 21
SI-BONE, Inc. Announces Board Changes Mar 10
SI-BONE, Inc. to Report Q4, 2020 Results on Mar 08, 2021 Feb 10 SI-BONE, Inc. Announces Resignation of Laura Francis from CFO
SI-BONE, Inc. Does Not Issue 2021 Financial Guidance due to COVID-19 Jan 08
New 90-day high: €20.80 Dec 11
Chairman recently sold €90k worth of stock Nov 20
Revenue beats expectations Nov 04
Third quarter 2020 earnings released: US$0.33 loss per share Nov 04
SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $70.181166 million. Oct 15
New 90-day high: €20.40 Oct 12
New 90-day high - €19.10 Sep 16
Chairman recently sold €55.0k worth of stock Aug 22
New 90-day high - €18.20 Aug 22
First half earnings released Aug 04
SI-BONE, Inc. to Report Q2, 2020 Results on Aug 03, 2020 Jul 22 Shareholder Returns 2K3 DE Medical Equipment DE Market 7D 7.2% -1.5% 0.7% 1Y -28.0% -7.0% 8.4%
See full shareholder returns
Return vs Market: 2K3 underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is 2K3's price volatile compared to industry and market? 2K3 volatility 2K3 Average Weekly Movement 9.5% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2K3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2K3's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 2008 344 Laura Francis si-bone.com
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion.
Show more SI-BONE, Inc. Fundamentals Summary How do SI-BONE's earnings and revenue compare to its market cap? 2K3 fundamental statistics Market cap €572.92m Earnings (TTM ) -€36.44m Revenue (TTM ) €153.01m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2K3 income statement (TTM ) Revenue US$157.04m Cost of Revenue US$35.02m Gross Profit US$122.02m Other Expenses US$159.42m Earnings -US$37.40m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.89 Gross Margin 77.70% Net Profit Margin -23.82% Debt/Equity Ratio 21.9%
How did 2K3 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 08:41 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SI-BONE, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Craig Bijou BofA Global Research Caitlin Cronin Canaccord Genuity William Plovanic Canaccord Genuity
Show 12 more analysts 
